Geneva, April 2013
Cell Culture Technologies enters into a collaboration with NovImmune for the generation of a robust CHO cell-based process platform for generating fully human bispecific monoclonal antibodies in fully synthetic minimal media.
We are happy to announce the start of a technical collaboration with NovImmune, Geneva, Switzerland, to establish a robust commercial-scale manufacturing platform for the kappa lambda body (kl-body), a novel fully human bispecific antibody format.
This new generation of biopharmaceutics considerably extends the application fields of current classical monoclonal antibodies. Fully synthetic, chemically defined media from Cell Culture Technologies and single-use bioreactors will be used to ensure process robustness and rapid production. The Institute of Physiology of the University of Zurich and the Institute of Biotechnology of the Zurich University of Applied Sciences (ZHAW) will focus on the analysis of product glycosylation and the cultivation of CHO cells in single-use bioreactors, respectively.
The project is supported by the Commission for Technology and Innovation (CTI) of the Swiss Confederation.